OncoSil Surges On Cancer Device CE Mark Plans
This article was originally published in PharmAsia News
Executive Summary
Australian medical device developer OncoSil Medical Limited saw its shares surge by a third on Mar. 16 after it announced that it would file for the CE Mark in both pancreatic and liver cancer indications in the second half of the year, on the back of clinical data that demonstrate its eponymous proprietary device technology is effective against two solid tumor types.